Phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of adagloxad simolenin (OBI-822) and OBI-821 treatment in patients with early-stage triple-negative breast cancer (TNBC) at high risk for recurrence.
Year: 2020
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, Unimed Medical Institute, Vall d'Hebron Institute of Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitätsklinikum Erlangen, Comprehensive Cancer Center Erlangen, National Taiwan University Hospital, Asan Medical Center, University of Ulsan, University of Chicago, University of Kansas Medical Center, University of California San Diego, Moores Cancer Center, Chinese Academy of Medical Sciences & Peking Union Medical College, Cancer Hospital of Chinese Academy of Medical Sciences
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W3029670301